Companies /Healthcare

Lantheus Holdings Inc

NASDAQ: LNTH Drug Manufacturers - Specialty & Generic
$100.25
▼ $0.14 (−0.14%) today
Markets closed · 7:20pm ET

Q1 2026 Earnings

Reported May 7, 2026, 7:36am ET · SEC source
$1.46
Beat +18.78%
EPS · est. $1.23
$377.3M
Beat +6.46%
Revenue · est. $354.4M
+9.1%
Beating market
LNTH vs S&P since report
4 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+3%+6%May 7May 8report 7:36am ETearnings+0.3%+3.4%
0+3%+6%May 7May 8earnings+0.3%+3.4%
LNTH +3.4%S&P 500 +0.3%
0+3%+6%May 7May 8report 7:36am ETearnings+1.9%+3.4%
0+3%+6%May 7May 8earnings+1.9%+3.4%
LNTH +3.4%NASDAQ +1.9%
−4%0+4%+8%May 6May 14report 7:36am ETearnings+1.8%+7.5%
−4%0+4%+8%May 6May 14earnings+1.8%+7.5%
LNTH +7.5%S&P 500 +1.8%
−4%0+4%+8%May 6May 14report 7:36am ETearnings+3.4%+7.5%
−4%0+4%+8%May 6May 14earnings+3.4%+7.5%
LNTH +7.5%NASDAQ +3.4%
+5.63%
Day of report
+2.26%
Next session
+6.23%
One week
+9.87%
30 days

S&P 500 over the same 30 days: +0.75%.

Did LNTH Beat Earnings? Q1 2026 Results

Lantheus delivered a clear beat to open fiscal 2026, posting first-quarter revenue of $377.33 million, up 1.2% year over year and ahead of the $354.42 million consensus by 6.46%, while adjusted EPS of $1.46 topped the $1.23 estimate by 18.78%. The headline driver was a portfolio in transition: PYLARIFY, the company's flagship PSMA PET imaging agent, faced competitive pressure that trimmed its contribution to $240.92 million, but that softness was offset by Neuraceq's $35.44 million addition following the Life Molecular Imaging acquisition and DEFINITY's 6.8% growth to $84.63 million. A significant regulatory catalyst added further momentum, as the FDA approved PYLARIFY TruVu, a reformulated version designed for manufacturing efficiency, with a phased commercial launch targeted for Q4 2026. Analysts raised price targets following the results, with shares responding positively to the combination of the beat and pipeline progress. Management reaffirmed full-year 2026 guidance of $1.40 billion to $1.45 billion in revenue and adjusted EPS of $5.00 to $5.25, pointing to accelerating growth beginning in 2027.

Key Takeaways
  • Strong DEFINITY sales growth of 6.8% year over year
  • Addition of Neuraceq revenue ($35.4 million) as a new revenue line in neurology
  • Gain on sale of SPECT business boosted GAAP net income
  • Strategic partnerships and other revenue grew 52.1%

“Our first quarter results demonstrate disciplined execution across the business, with strong performance from PYLARIFY, Neuraceq, and DEFINITY, and continued progress against the priorities that underpin our long-term strategy.”

Lantheus CEO, on the earnings call

Forward Guidance & Outlook

Lantheus reaffirmed its full-year 2026 guidance: revenue of $1.4 billion to $1.45 billion and adjusted fully diluted EPS of $5.00 to $5.25, unchanged from guidance issued on February 26, 2026. The company plans a phased geographic launch of PYLARIFY TruVu beginning in Q4 2026, is focused on sustaining PSMA PET leadership, expanding its Alzheimer's imaging portfolio, and advancing its prioritized pipeline. Management indicated growth acceleration is expected beginning in 2027 and signaled disciplined capital deployment focused on radiodiagnostics while evaluating value-maximizing alternatives for radiotherapeutic assets.

LNTH YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$0$200.0M$400.0M$372.7M$377.3MRevenue$237.7M$230.9MGross Profit$102.1M$81.3MOperating Income$72.9M$118.4MNet Income
$0$200.0M$400.0MRevenueGross ProfitOperating IncomeNet Income

LNTH Revenue by Segment

PYLARIFY$240.9M−6.5%
DEFINITY$84.6M+6.8%
Neuraceq$35.4M+100.0%
TechneLite
Strategic partnerships and other revenue
Strategic partnerships and other$16.3M+52.1%
Other precision diagnostics

Figures from SEC filings and company reports. Not investment advice.